Perspective Therapeutics (CATX) Shares Outstanding (Weighted Average) (2010 - 2026)

Perspective Therapeutics has disclosed Shares Outstanding (Weighted Average) across 17 years of filings, most recently posting $103.6 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $103.6 million, up 43.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $103.6 million (up 43.18% YoY), and the FY2025 annual result was $338715.0, down 99.47% from the prior year.
• Shares Outstanding (Weighted Average) came in at $103.6 million for Q1 2026 at Perspective Therapeutics, up from $338715.0 in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $228.6 million in Q1 2023 to a low of $264573.0 in Q4 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $70.6 million (2024), against an average of $75.1 million.
• Across the five-year window, Shares Outstanding (Weighted Average) slumped 99.81% in 2022 and jumped 11083.67% in 2024, its largest moves.
• Perspective Therapeutics' Shares Outstanding (Weighted Average) stood at $264573.0 in 2022, then soared by 117.73% to $576063.0 in 2023, then surged by 11083.67% to $64.4 million in 2024, then plunged by 99.47% to $338715.0 in 2025, then soared by 30487.37% to $103.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $103.6 million (Q1 2026), $338715.0 (Q4 2025), and $74.3 million (Q3 2025), per Business Quant data.